Indaptus Therapeutics, Inc. (INDP): Nasdaq/NYSE listing notice — Indaptus receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period

Indaptus Therapeutics, Inc.

Received Nasdaq notice on Jan 31, 2025 for non-compliance with minimum bid price of $1.00 per share.
Bid price below $1.00 for 30 consecutive business days triggered the notice.
Has 180 calendar days (until July 30, 2025) to regain compliance.
To cure, closing bid must be at least $1.00 for 10 consecutive business days.
May consider reverse stock split; second 180-day period available if other standards met.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Indaptus Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 31, 2025, Indaptus Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busi

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Indaptus Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 31, 2025, Indaptus Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements

View on SEC.gov

Browse all listing & compliance notices →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-004428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.